Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COZAAR vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Losartan is a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. It also reduces proteinuria and slows progression of renal disease by decreasing intraglomerular pressure.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Hypertension,Nephropathy in patients with type 2 diabetes and hypertension,Hypertension with left ventricular hypertrophy (to reduce risk of stroke)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Plasma half-life of losartan: approximately 2 hours; active metabolite E-3174: 6–9 hours. Clinical context: once-daily dosing due to prolonged receptor blockade by metabolite
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Losartan is extensively metabolized in the liver via CYP2C9 and CYP3A4 to its active metabolite, E-3174, which is more potent than the parent drug. E-3174 is further metabolized to inactive metabolites. Both losartan and E-3174 are excreted in urine and feces.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal (35% as unchanged drug and 18% as active metabolite), biliary/fecal (approximately 60% of radiolabeled dose recovered in feces)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
≥99% (primarily albumin); losartan ≥98.7%, active metabolite ≥99.8%
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Losartan: 34 L (0.47 L/kg for 70 kg adult); active metabolite: 12 L. Indicates limited extravascular distribution
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: about 33% (losartan); active metabolite bioavailability not directly reported but formed via first-pass metabolism
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, initial dose is 25 mg orally once daily.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
For Child-Pugh Class A or B: initial dose is 25 mg orally once daily; no data for Class C.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For children ≥6 years: initial dose 0.7 mg/kg (up to 50 mg) orally once daily; maximum 1.4 mg/kg (up to 100 mg) once daily.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Consider lower initial dose of 25 mg orally once daily due to potential for volume depletion or decreased renal function.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Fetal toxicity (discontinue when pregnancy is detected); hypotension in volume-depleted patients; renal impairment (monitor serum creatinine and potassium); hyperkalemia; angioedema; dual blockade of renin-angiotensin system (increased risk of hypotension, hyperkalemia, renal dysfunction); hepatotoxicity; monitor for azotemia in renovascular hypertension.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to losartan or any component; pregnancy (especially second and third trimesters); concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (e GFR <60 m L/min/1.73m²); history of angioedema related to previous ARB therapy.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No significant food interactions. However, avoid high-potassium foods (such as bananas, oranges, leafy greens, tomatoes, and avocados) in large amounts if taken with potassium supplements or if renal function is impaired. Limit salt intake as advised for hypertension management. Grapefruit juice does not interact significantly with losartan.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Contraindicated in pregnancy. First trimester: Associated with congenital malformations, including renal dysplasia and oligohydramnios. Second and third trimesters: Fetal toxicity (oligohydramnios, pulmonary hypoplasia, skull ossification defects, neonatal anuria, hypotension, and death).
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Not recommended. No data on M/P ratio; excreted in rat milk; potential for adverse effects in nursing infant due to renin-angiotensin system blockade.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Contraindicated; no dose adjustments recommended as use should be avoided; alternative antihypertensives preferred.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Cozaar (losartan) is an angiotensin II receptor blocker (ARB). Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation and periodically thereafter. May cause a reversible rise in serum creatinine, especially in renal artery stenosis. Has a uricosuric effect, modestly lowering uric acid levels. Avoid use in pregnancy (category D). Dose adjustment recommended for hepatic impairment. Can be used as an alternative in patients who develop ACE-inhibitor-induced cough.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take once daily with or without food; consistency in timing is key.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,May cause dizziness, especially at start; avoid driving until you know how it affects you.,Do not use if pregnant, planning pregnancy, or breastfeeding; discuss contraception with your doctor.,Report symptoms like fainting, rapid heartbeat, or leg swelling to your doctor.,Stay well-hydrated, especially if you experience diarrhea or vomiting, as dehydration can worsen side effects.,Do not stop this medication abruptly; consult your physician before discontinuing.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COZAAR vs ABSTRAL, answered by our medical review team.
COZAAR is a Angiotensin Receptor Blocker that works by Losartan is a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. It also reduces proteinuria and slows progression of renal disease by decreasing intraglomerular pressure.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COZAAR and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COZAAR is: 50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COZAAR and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COZAAR is classified as Category C. Contraindicated in pregnancy. First trimester: Associated with congenital malformations, including renal dysplasia and oligohydramnios. Second and third trimesters: Fetal toxicity . ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.